Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...
R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, São Paulo, SP, 05403 903, Brazil Tel.: +55 11 3061 7457 Fax: +55 11 3081 7190 [email protected] Establishing that ...
Substantial basic science and clinical evidence suggests that excess tumor necrosis factor-alpha (TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. In addition to its ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...
A study lead by the University of Barcelona opens new perspectives to better understand how the molecular mechanisms involved in regenerative medicine work. The study focuses on tumour necrosis factor ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
A team of researchers in the United States has discovered a novel mechanism in which a key protein drives the inflammatory damage associated with rheumatoid arthritis. The foundational finding is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback